Finally, we bring attention to a novel phase I trial of small extracellular vesicles (sEVs) delivering miR-34a, which represents a first-in-human effort to re-establish p53-related immune control via RNA-based nanomedicine in TP53-mutant CLL 60-62. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.